Aeglea Biotherapeutics Inc (AGLE) USD0.0001
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a human enzyme therapeutics as advanced solutions for rare and other high-burden diseases. The Company’s product candidates are Pegzilarginase, ACN00177 and AEB5100. Its Pegzilarginase is a recombinant human Arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase One Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its ACN00177 is a PEGylated or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.